Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $311.52 million. The enterprise value is $238.90 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 54.37 million shares outstanding. The number of shares has increased by 6.76% in one year.
| Current Share Class | 42.70M |
| Shares Outstanding | 54.37M |
| Shares Change (YoY) | +6.76% |
| Shares Change (QoQ) | +3.00% |
| Owned by Insiders (%) | 17.68% |
| Owned by Institutions (%) | 62.65% |
| Float | 36.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.40 |
| Forward PS | 1.80 |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.62, with a Debt / Equity ratio of 0.65.
| Current Ratio | 5.62 |
| Quick Ratio | 5.44 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5,092.73 |
Financial Efficiency
Return on equity (ROE) is -60.34% and return on invested capital (ROIC) is -23.74%.
| Return on Equity (ROE) | -60.34% |
| Return on Assets (ROA) | -19.67% |
| Return on Invested Capital (ROIC) | -23.74% |
| Return on Capital Employed (ROCE) | -37.69% |
| Revenue Per Employee | $272,234 |
| Profits Per Employee | -$655,910 |
| Employee Count | 834 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -479,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.65% in the last 52 weeks. The beta is 1.24, so DNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -87.65% |
| 50-Day Moving Average | 10.18 |
| 200-Day Moving Average | 9.95 |
| Relative Strength Index (RSI) | 31.17 |
| Average Volume (20 Days) | 1,269,811 |
Short Selling Information
The latest short interest is 9.98 million, so 18.35% of the outstanding shares have been sold short.
| Short Interest | 9.98M |
| Short Previous Month | 8.75M |
| Short % of Shares Out | 18.35% |
| Short % of Float | 27.18% |
| Short Ratio (days to cover) | 4.85 |
Income Statement
In the last 12 months, DNA had revenue of $227.04 million and -$547.03 million in losses. Loss per share was -$10.54.
| Revenue | 227.04M |
| Gross Profit | 182.50M |
| Operating Income | -478.72M |
| Pretax Income | -897.68M |
| Net Income | -547.03M |
| EBITDA | -415.70M |
| EBIT | -478.72M |
| Loss Per Share | -$10.54 |
Full Income StatementBalance Sheet
The company has $561.57 million in cash and $467.76 million in debt, giving a net cash position of $93.82 million or $1.73 per share.
| Cash & Cash Equivalents | 561.57M |
| Total Debt | 467.76M |
| Net Cash | 93.82M |
| Net Cash Per Share | $1.73 |
| Equity (Book Value) | 716.06M |
| Book Value Per Share | 13.17 |
| Working Capital | 495.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$319.59 million and capital expenditures -$62.54 million, giving a free cash flow of -$382.13 million.
| Operating Cash Flow | -319.59M |
| Capital Expenditures | -62.54M |
| Free Cash Flow | -382.13M |
| FCF Per Share | -$7.03 |
Full Cash Flow StatementMargins
Gross margin is 80.38%, with operating and profit margins of -210.85% and -240.94%.
| Gross Margin | 80.38% |
| Operating Margin | -210.85% |
| Pretax Margin | -241.15% |
| Profit Margin | -240.94% |
| EBITDA Margin | -183.09% |
| EBIT Margin | -210.85% |
| FCF Margin | n/a |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.76% |
| Shareholder Yield | n/a |
| Earnings Yield | -164.41% |
| FCF Yield | -114.85% |
Dividend DetailsAnalyst Forecast
The average price target for DNA is $17.25, which is 201.05% higher than the current price. The consensus rating is "Sell".
| Price Target | $17.25 |
| Price Target Difference | 201.05% |
| Analyst Consensus | Sell |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 0.025:1.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.025:1 |
Scores
DNA has an Altman Z-Score of -5.33 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.33 |
| Piotroski F-Score | 3 |